RT Journal Article
SR Electronic
T1 Aspergillus fumigatus sensitization in COPD and smokers
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA3610
DO 10.1183/13993003.congress-2015.PA3610
VO 46
IS suppl 59
A1 Stephanie Everaerts
A1 Erna Van Hoeyveld
A1 Kristina Vermeersch
A1 Lieven Dupont
A1 Bart Vanaudenaerde
A1 Xavier Bossuyt
A1 Katrien Lagrou
A1 Wim Janssens
YR 2015
UL http://erj.ersjournals.com/content/46/suppl_59/PA3610.abstract
AB The clinical impact of sensitization to Aspergillus fumigatus (Aspf) in COPD is not well understood. We investigated sensitization to Aspf and its recombinant allergens in a large cohort of COPD patients and smokers. We included 350 patients with mild to severe COPD and 50 healthy smokers. Aspf IgG, Aspf IgE and IgE to recombinant allergens (r Asp f1, f2, f3, f4 and f6) were measured on plasma samples by the ImmunoCAP system. Sensitization to Aspf or to one of its recombinant allergens was more frequent in COPD compared to smoking controls; 16.6% versus 4% (p=0.0185). Presence of Aspf IgG was not significantly different (22% versus 16%, p=0.3320). Within the COPD patients, sensitized subjects had a lower mean BMI and a lower mean diffusion capacity than non-sensitized patients. Furthermore, sensitized COPD patients tended to have a lower mean FEV1 and more exacerbations than non-sensitized COPD patients. Significantly more sensitized COPD patients had a modified Reiff score for bronchiectasis of at least 2 compared to non-sensitized COPD patients. COPD sensitizedCOPD non-sensitizedp valueSubjects58292BMI23.6 (15.8-36.3)25.1 (14.0-50.0)0.0433pack-years smoked53.2 (18-101)52.38 (10-170)0.8010≥2 exacerbations previous year,%48.335.60.0692FEV1 %predicted46.8 (19-100)52.7 (16-134)0.0598DLCO %predicted47.7 (17-111)53.2 (15-113)0.0453Modified Reiff score≥2,%44.830.10.0292Aspf IgG>50mg/L,%41.418.2<0.0001Data are presented as n, mean (range) or proportion.Patients with COPD have a higher prevalence of sensitization to Aspergillus fumigatus compared to smokers with normal lung function. These sensitized COPD patients have worse clinical characteristics compared to non-sensitized COPD patients.